Annexon

Summary

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated neurodegeneration. Its product candidates include ANX005, a monoclonal antibody, which is in Phase II/III clinical trials to treat patients with guillain- barré syndrome; Phase II trial in patients with warm autoimmune hemolytic anemia; and Phase II clinical trial for Huntington's disease and amyotrophic lateral sclerosis. The company is also developing ANX009 that is in Phase Ib trial in patients with lupus nephritis; and ANX007, which is in Phase II clinical trials to treat patients with geographic atrophy. In addition, it develops ANX105, an investigational monoclonal antibody targeting neurodegenerative indications; and ANX1502, an investigational oral small molecule for the treatment of certain autoimmune indications. The company was incorporated in 2011 and is headquartered in Brisbane, California.

History

Annexon was founded in2010 by a group of eminent scientists, entrepreneurs, and industry veterans to unlock the potential of IgG regulation. The company has since grown to become a leading biotechnology company in the field of IgG regulation. Annexon has developed a platform technology to identify and develop therapeutics targeting a wide range of IgG-related diseases.

Mission

Our mission is to leverage our deep understanding of IgG regulation and bring to market therapeutics that improve the lives of patients with immune-mediated conditions.

Vision

To be the leader in IgG Biology and the pioneer in IgG-targeted therapeutics to better the lives of patients.

References

https://in.investing.com/equities/annexon-inc

https://finance.yahoo.com/quote/ANNX/profile?p=ANNX

https://www.crunchbase.com/organization/annexon-biosciences

https://companiesmarketcap.com/

https://www.annexonbio.com

Contacts

Follow Us

Annexon

Share

Contacts

Follow Us